Journal of Thrombosis and Thrombolysis

, Volume 13, Issue 1, pp 41–47



  • Sekar Kathiresan
    • Cardiology DivisionMassachusetts General Hospital, Harvard Medical School
  • Jin Shiomura
    • Mitsubishi Pharma Corporation
  • Ik-Kyung Jang
    • Cardiology DivisionMassachusetts General Hospital, Harvard Medical School

DOI: 10.1023/A:1015368126304

Cite this article as:
Kathiresan, S., Shiomura, J. & Jang, I. J Thromb Thrombolysis (2002) 13: 41. doi:10.1023/A:1015368126304


Antithrombotic and antiplatelet therapies are the cornerstones of management of cardiovascular disorders today. Due to the safety and efficacy limitations of the classic antithrombotic, unfractionated heparin, considerable effort has been directed at developing novel anticoagulants. Direct thrombin inhibitors as a class of drugs offer inhibition of clot-bound as well as fluid-phase thrombin and a more predictable anticoagulant response. Specifically, argatroban, a synthetic small molecule direct thrombin inhibitor, selectively inhibits the catalytic site of thrombin in a reversible manner. Overall, argatroban's short half-life, ease of monitoring with an activated partial thromboplastin time, and safety in renal failure patients make this drug the preferable mode therapy for prevention of thrombosis in heparin-induced thrombocytopenia. The role of adjunctive argatroban therapy in acute coronary syndromes and during percutaneous coronary intervention is currently being studied.

argatrobananticoagulationdirect thrombin inhibitor
Download to read the full article text

Copyright information

© Kluwer Academic Publishers 2002